This Amendment No. 1 amends the Schedule 13G originally filed with the SEC on February 2, 2022 (the “Schedule”) to report and reflect that Novo Holdings A/S ceased to be a beneficial owner of more than five percent of the Issuer’s Ordinary Shares due to Recursion Pharmaceuticals, Inc.’s (“Recursion”) purchase of Novo Holding A/S’s Ordinary Shares in Recursion’s acquisition of the entire issued share capital of the Issuer.
Item 1. | (a) Name of Issuer: |
Exscientia plc
(b) Address of Issuer’s Principal Executive Offices:
The Schrodinger Building, Oxford Science Park
Oxford, United Kingdom, OX4 4GE
Item 2. | (a) Name of Person Filing: |
Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the “Foundation”), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S and Novozymes A/S) and is responsible for managing the Foundation’s assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.
(b) Address or Principal Business Office or, if none, Residence:
Tuborg Havnevej 19
2900 Hellerup, Denmark
(c) Citizenship or Place of Organization:
Denmark
(d) Title of Class of Securities:
Ordinary Shares
(e) CUSIP Number:
30223G102
Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
3